{"transactions":[{"id":1058489,"issuer":{"id":5974,"kind":"organization","name":"CapsoVision, Inc","symbol":"CV"},"owners":[{"id":76200,"kind":"person","name":"Petersen Rebecca Ann","position":1,"cik":"0002075458","reported_name":"Petersen Rebecca Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Director of Clinical Affairs"}}],"security":"Stock Option (right to buy)","published_at":"2025-08-22T20:44:52.000Z","date":"2025-08-18","kind":"exercise","planned":false,"acquired":false,"shares":17327,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These options were previously reported at exercise price of $0.11 per share. The exercise price reported herein gives effect to a 1-for-3.33 reverse stock split effected by the Issuer on July 2, 2025 in connection with its initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option was granted on March 23, 2022 and is partially vested and exercisable as of the transaction date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"There options were previously reported as covering 25,000 and 70,000 shares, respectively. The number of shares reported herein gives effect to a 1-for-3.33 reverse stock split effected by the Issuer on July 2, 2025 in connection with its initial public offering."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"There options were previously reported as covering 25,000 and 70,000 shares, respectively. The number of shares reported herein gives effect to a 1-for-3.33 reverse stock split effected by the Issuer on July 2, 2025 in connection with its initial public offering."}],"balance_after":3694,"derivative":{"exercise_price":0.3663,"expiration_date":"2032-03-22","underlying":"Common Stock","underlying_shares":17327},"source":{"system":"sec-edgar","filing":"0001378325-25-000014","document":"wk-form4_1755909887.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2075458/000137832525000014/wk-form4_1755909887.xml","form_type":"4"}},{"id":1058488,"issuer":{"id":5974,"kind":"organization","name":"CapsoVision, Inc","symbol":"CV"},"owners":[{"id":76200,"kind":"person","name":"Petersen Rebecca Ann","position":1,"cik":"0002075458","reported_name":"Petersen Rebecca Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Director of Clinical Affairs"}}],"security":"Stock Option (right to buy)","published_at":"2025-08-22T20:44:52.000Z","date":"2025-08-18","kind":"exercise","planned":false,"acquired":false,"shares":7507,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These options were previously reported at exercise price of $0.11 per share. The exercise price reported herein gives effect to a 1-for-3.33 reverse stock split effected by the Issuer on July 2, 2025 in connection with its initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was granted on October 28, 2021 and is fully vested and exercisable as of the transaction date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"There options were previously reported as covering 25,000 and 70,000 shares, respectively. The number of shares reported herein gives effect to a 1-for-3.33 reverse stock split effected by the Issuer on July 2, 2025 in connection with its initial public offering."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"There options were previously reported as covering 25,000 and 70,000 shares, respectively. The number of shares reported herein gives effect to a 1-for-3.33 reverse stock split effected by the Issuer on July 2, 2025 in connection with its initial public offering."}],"balance_after":0,"derivative":{"exercise_price":0.3663,"expiration_date":"2031-10-31","underlying":"Common Stock","underlying_shares":7507},"source":{"system":"sec-edgar","filing":"0001378325-25-000014","document":"wk-form4_1755909887.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2075458/000137832525000014/wk-form4_1755909887.xml","form_type":"4"}},{"id":1058487,"issuer":{"id":5974,"kind":"organization","name":"CapsoVision, Inc","symbol":"CV"},"owners":[{"id":76200,"kind":"person","name":"Petersen Rebecca Ann","position":1,"cik":"0002075458","reported_name":"Petersen Rebecca Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Director of Clinical Affairs"}}],"security":"Common Stock","published_at":"2025-08-22T20:44:52.000Z","date":"2025-08-18","kind":"exercise","planned":false,"acquired":true,"shares":24834,"price":0.3663,"value":9096.6942,"ownership":{"direct":true},"balance_after":24834,"source":{"system":"sec-edgar","filing":"0001378325-25-000014","document":"wk-form4_1755909887.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2075458/000137832525000014/wk-form4_1755909887.xml","form_type":"4"}}]}